Decentralized Trials Guidance May Reflect US FDA’s Lessons Learned During COVID-19

 
• By Sue Sutter

Work on guidance that was originally expected in 2020 continues as the agency and industry learn more about the utility and spectrum of decentralized trials as a result of the novel coronavirus pandemic.

stethoscope and a smartphone with a medical app, copyspace (3d render)
Decentralized trials offer a more patient-centric approach to data collection. • Source: Shutterstock

More from Clinical Trials

More from R&D